Revance Therapeutics Inc (RVNC)

[DewDiligence]

RVNC 7/23/20 fully-diluted shares=86.35M.

The above figure consists of: 57.31M basic shares on the 6/30/20 balance sheet (https://www.sec.gov/ix?doc=/Archives/edgar/data/1479290/000147929020000090/rvnc-20200630.htm#i7c00b49d51464ae7929d790a639b9955_16 ); 8.44M options and unvested restricted stock as of 6/30/20 (ibid p16); 9.37M shares and options issued for the HintMd acquisition, which closed in Jul 2020 (ibid, p20); 2.35M shares for future equity grants allocated in Jul 2020, mostly pursuant to the Hint MD acquisition (https://www.sec.gov/Archives/edgar/data/1479290/000119312520197940/d883422ds8.htm); and 8.88M shares deriving from the convertible debt issued in Feb 2020 (https://www.sec.gov/ix?doc=/Archives/edgar/data/1479290/000147929020000090/rvnc-20200630.htm#i7c00b49d51464ae7929d790a639b9955_16 p16; ignoring hedging transactions associated with the convertible debt).

Excluding the shares derived from the convertible debt, the number of fully-diluted shares at 7/23/20 was 77.47.